February 20, 2019
1 min read

Bausch Health acquires anti-itch drop under study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Bausch Health Companies and Eton Pharmaceuticals announced that a subsidiary of Bausch Health has acquired the U.S. rights to Eton Pharmaceuticals investigational eye drop.

Once FDA-approved, the agent would be an over-the-counter preservative-free formulation for the treatment of ocular itching associated with allergic conjunctivitis, Bausch said in a press release.

EM-100 has been submitted to the FDA for review, according to the company press release.

Previously, Eton Pharmaceuticals reported positive results from a phase 3 trial where the eye drop showed statistically significant superiority to placebo and no adverse events and demonstrated noninferiority to a comparator product for ocular itching.